On September 11, 2023 Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, reported that management will present at the following investor conferences in September (Press release, Immunocore, SEP 11, 2023, View Source [SID1234635067]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Healthcare Conference
Fireside Chat: Monday, September 11, 2023, at 2:30 p.m. EDT
Morgan Stanley Healthcare Conference
Fireside Chat: Tuesday, September 12, 2023, at 5:30 p.m. EDT
Baird Healthcare Conference
1×1 and small group meetings: Wednesday, September 13, 2023
2023 Cantor Global Healthcare Conference
Fireside Chat: Thursday, September 28, 2023, at 8:00 a.m. EDT

Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the events, a replay of the presentations will be made available for a limited time.